Media stories about Dicerna Pharmaceuticals (NASDAQ:DRNA) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Dicerna Pharmaceuticals earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.6188098327956 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media stories that may have impacted Accern’s scoring:
- Global Primary Hyperoxaluria Drug Market 2018 – OxThera AB, Intellia Therapeutics Inc, Dicerna Pharmaceuticals Inc … (healthcaretrends24.com)
- Dicerna to Present at the HC Wainwright Global Life Sciences Conference (businesswire.com)
- Dicerna to Present at the H.C. Wainwright Global Life Sciences Conference (finance.yahoo.com)
- Dicerna Pharmaceuticals (DRNA) Upgraded by ValuEngine to “Hold” (americanbankingnews.com)
- Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Post Quarterly Sales of $1.75 Million (americanbankingnews.com)
DRNA has been the subject of several research reports. ValuEngine upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. B. Riley began coverage on Dicerna Pharmaceuticals in a research note on Wednesday, March 28th. They issued a “neutral” rating and a $10.00 target price for the company. BidaskClub upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, January 25th. Zacks Investment Research downgraded Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, February 1st. Finally, SunTrust Banks assumed coverage on Dicerna Pharmaceuticals in a research report on Monday, February 5th. They set a “buy” rating and a $13.00 price target for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $12.04.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.25). The business had revenue of $1.40 million during the quarter, compared to the consensus estimate of $1.45 million. Dicerna Pharmaceuticals had a negative return on equity of 171.81% and a negative net margin of 2,637.15%. The company’s quarterly revenue was up 976.9% on a year-over-year basis. sell-side analysts forecast that Dicerna Pharmaceuticals will post -1.15 earnings per share for the current year.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.